Single Center, Open-Label, Single-Sequence, Within-Subject Study In Two Cohorts Of Healthy Male Subjects Comparing Single-Dose Pharmacokinetics Of Fedovapagon Alone And In Combination With A CYP3A4 Inhibitor, Itraconazole, Or A CYP3A4 Inducer, Rifampicin
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2015
At a glance
- Drugs Fedovapagon (Primary) ; Itraconazole; Rifampicin
- Indications Nocturia
- Focus Pharmacokinetics
- Sponsors Vantia Therapeutics
- 29 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 May 2015 New trial record